Maurie Markman, MD

Disclosures

May 26, 2017

Hello . This is Dr Maurie Markman from the Cancer Treatment Centers of America in Philadelphia. I want to briefly discuss the just-released abstracts for the gynecologic cancer session of the upcoming American Society of Clinical Oncology (ASCO) annual meeting.

The oral and poster sessions are going to be very interesting. In these meetings we usually see studies that are focused on chemotherapy. From what I can tell, there are certainly no studies that will change the standard of care in the chemotherapeutic management of ovarian cancer. It is important to note that results of several important phase 3 randomized surgical trials in the malignancy will be presented. One looked at the potential impact of secondary cytoreductive surgery in recurrent disease.[1] A second trial looked at the potential role of hyperthermic intraperitoneal chemotherapy.[2] And a third prospective study looked at the potential role of lymphadenectomy.[3]

There are also long-term follow-up survival data on a number of trials, both in ovarian cancer[4,5] and in endometrial cancer.[6] There are data on checkpoint inhibitor follow-up[7,8,9] and a number of other novel strategies[10,11] being reported at this meeting in the phase 1/early phase 2 setting.

For those interested in new studies and strategies, as well as results of important phase 3 randomized trials, this will be a very interesting meeting with some very interesting sessions. I certainly am looking forward to hearing both the presentations and the discussions.

Thank you for your attention.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....